ArticleBMC cancer2015

Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.

Christina L Grek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.